Literature DB >> 3181274

EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs.

J P Davignon1, J A Slack, J H Beijnen, W R Vezin, T J Schoemaker.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3181274     DOI： 10.1016/0277-5379(88)90349-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  6 in total

1.  Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.

Authors:  J D Jonkman-de Vries; J J Kettenes-van den Bosch; R E Henrar; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.

Authors:  S C van der Schoot; B Nuijen; A D R Huitema; J H Beijnen
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

3.  Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).

Authors:  J D Jonkman-de Vries; M J de Graaff-Teulen; R E Henrar; J J Kettenes-van den Bosch; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.

Authors:  J D Jonkman-de Vries; H Talsma; R E Henrar; J J Kettenes-van den Bosch; A Bult; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].

Authors:  J D Jonkman-de Vries; H Rosing; H Talsma; R E Henrar; J J Kettenes-van den Bosch; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

6.  CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

Authors:  J H Beijnen; K P Flora; G W Halbert; R E Henrar; J A Slack
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.